ClouDr Group (FRA:H3L) EBIT: €-115.5 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H3L ClouDr Group Ltd FRA:H3L
48 GF Score
Price €0.05
GF Value €0.08
! 9 Warning Signs
View Full Analysis

What is ClouDr Group EBIT?

ClouDr Group FRA:H3L 48 EBIT is €-115.5 Mil as of Dec. 2025. GuruFocus rates FRA:H3L with a GF Score™ of 48/100 and a GF Value™ of €0.08. The stock has 9 warning signs investors should review.

ClouDr Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-38.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-115.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ClouDr Group's annualized ROC % for the quarter that ended in Dec. 2025 was 25.62%. ClouDr Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -554.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ClouDr Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -960.21%.

ClouDr Group  (FRA:H3L) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ClouDr Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=39.738 * ( 1 - 0% )/( (162.082 + 148.127)/ 2 )
=39.738/155.1045
=25.62 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=260.201 - 66.107 - ( 53.767 - max(0, 153.875 - 185.887+53.767))
=162.082

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=204.188 - 52.121 - ( 49.78 - max(0, 138.801 - 142.741+49.78))
=148.127

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

ClouDr Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-77.668/( ( (14.602 + max(2.446, 0)) + (10.986 + max(-17.998, 0)) )/ 2 )
=-77.668/( ( 17.048 + 10.986 )/ 2 )
=-77.668/14.017
=-554.10 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(57.549 + 21.254 + 40.792) - (66.107 + 0 + 51.042)
=2.446

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.831 + 19.604 + 27.596) - (52.121 + 0 + 53.908)
=-17.998

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ClouDr Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-115.494/12.028
=-960.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClouDr Group EBIT Related Terms

ClouDr Group EBIT Historical Data

* Premium members only.

The historical data trend for ClouDr Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClouDr Group EBIT Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -576.06 -228.24 -40.65 -62.16 -115.82

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.77 -14.02 -47.79 -76.66 -38.83

FRA:H3L vs MCK, COR, CAH: EBIT Comparison

For the Medical Distribution subindustry, ClouDr Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ClouDr Group EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, ClouDr Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ClouDr Group's EV-to-EBIT falls into.


FRA:H3L
48GF Score
ClouDr Group Ltd FRA:H3L
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClouDr Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-115.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-115.5 Mil mean?
ClouDr Group (FRA:H3L) has a EBIT of €-115.5 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ClouDr Group.
Is ClouDr Group's EBIT too high?
ClouDr Group's current EBIT is €-115.5 Mil. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's EBIT compare to MCK and COR?
ClouDr Group's EBIT of €-115.5 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ClouDr Group. ClouDr Group's current EBIT is €-115.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current EBIT of €-115.5 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current EBIT is €-115.5 Mil. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current EBIT is €-115.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClouDr Group (FRA:H3L) Overvalued in 2026?

Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued. The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.

Key valuation signals for FRA:H3L:

  • EBIT: €-115.5 Mil
  • GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
  • GF Score™: 48/100 with 9 warning signs

No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClouDr Group Business Description

Other Exchanges 09955:Hong Kong
Address No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score

Get the complete analysis for FRA:H3L

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price
€0.08
GF Value